Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.30 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7066446 | 0.99 | TP53 (0.31) | TP53ALOX12LMNAPDE4APDE4B | |
| SCHEMBL7064873 | 0.94 | TP53 (0.30) | TP53ALOX12 | |
| Hydrochloric Acid SCHEMBL7068329 | 0.93 | TP53 (0.30) | TP53ALOX12 | |
| Hydrochloric Acid SCHEMBL7066458 | 0.84 | GABRA1 (0.36) | LMNAGABRA1 | |
| SCHEMBL7065148 | 0.83 | USP30 (0.33) | LMNA | |
| Hydrochloric Acid SCHEMBL7065326 | 0.83 | USP30 (0.33) | — | |
| SCHEMBL7068740 | 0.80 | USP30 (0.33) | — | |
| SCHEMBL7065320 | 0.79 | ACE (0.32) | LMNA | |
| SCHEMBL7070983 | 0.77 | GRIK1 (0.36) | — | |
| Hydrochloric Acid SCHEMBL7066442 | 0.76 | GRIK1 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6579886-B2 | Ionotropic glutamate receptors; 6-((4-carboxylic acid-1H-imidazol-1-yl)methyl)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3 -carboxylic acid | ELI LILLY AND COMPANY | 2003-06-17 | — | — | US | disclosed |
| US-20030055081-A1 | Selective iglur5 receptor antagonists | ELI LILLY AND COMPANY | 2003-03-20 | — | — | US | disclosed |
| EP-1257545-A1 | SELECTIVE iGLUR 5? RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2002-11-20 | — | — | EP | disclosed |
| WO-2001046173-A1 | SELECTIVE iGLUR5 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055081-A1 | Selective iglur5 receptor antagonists | GRM5, GRIK5, GPR35 | TP53 4877/4885ALOX12 1670/4885LMNA 3014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.